Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) Given Consensus Rating of “Buy” by Analysts

Eyepoint Pharmaceuticals, Inc. (NASDAQ:EYPT) has been assigned an average recommendation of “Buy” from the eight research firms that are presently covering the firm, MarketBeat Ratings reports. One research analyst has rated the stock with a sell recommendation, five have given a buy recommendation and two have issued a strong buy recommendation on the company. The average 1 year price objective among brokerages that have issued ratings on the stock in the last year is $37.8333.

EYPT has been the subject of several research analyst reports. HC Wainwright lifted their price target on Eyepoint Pharmaceuticals from $23.00 to $30.00 and gave the stock a “buy” rating in a research note on Thursday, March 5th. Chardan Capital lifted their price target on Eyepoint Pharmaceuticals from $27.00 to $29.00 and gave the stock a “buy” rating in a research note on Wednesday, March 4th. Royal Bank Of Canada decreased their price objective on Eyepoint Pharmaceuticals from $39.00 to $37.00 and set an “outperform” rating on the stock in a report on Thursday, May 7th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Eyepoint Pharmaceuticals in a report on Tuesday, April 21st. Finally, Guggenheim reiterated a “buy” rating and issued a $68.00 price objective on shares of Eyepoint Pharmaceuticals in a report on Wednesday.

Insider Activity at Eyepoint Pharmaceuticals

In other news, insider Ramiro Ribeiro sold 2,437 shares of Eyepoint Pharmaceuticals stock in a transaction dated Friday, April 17th. The stock was sold at an average price of $15.00, for a total value of $36,555.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Corporate insiders own 5.13% of the company’s stock.

Institutional Inflows and Outflows

Several large investors have recently modified their holdings of the stock. Stempoint Capital LP increased its holdings in shares of Eyepoint Pharmaceuticals by 129.1% in the first quarter. Stempoint Capital LP now owns 810,764 shares of the company’s stock worth $10,451,000 after buying an additional 456,915 shares during the period. Janus Henderson Group PLC increased its holdings in shares of Eyepoint Pharmaceuticals by 22.6% in the first quarter. Janus Henderson Group PLC now owns 3,601,168 shares of the company’s stock worth $46,419,000 after buying an additional 663,439 shares during the period. California State Teachers Retirement System increased its holdings in Eyepoint Pharmaceuticals by 2,158.3% during the 1st quarter. California State Teachers Retirement System now owns 105,101 shares of the company’s stock valued at $1,355,000 after purchasing an additional 100,447 shares during the period. The Manufacturers Life Insurance Company increased its holdings in Eyepoint Pharmaceuticals by 58.4% during the 1st quarter. The Manufacturers Life Insurance Company now owns 36,072 shares of the company’s stock valued at $465,000 after purchasing an additional 13,297 shares during the period. Finally, Commodore Capital LP purchased a new position in Eyepoint Pharmaceuticals during the 1st quarter valued at about $36,414,000. Hedge funds and other institutional investors own 99.41% of the company’s stock.

Eyepoint Pharmaceuticals Stock Down 0.4%

Shares of EYPT stock opened at $13.66 on Friday. The business has a 50-day moving average price of $13.23 and a two-hundred day moving average price of $14.59. Eyepoint Pharmaceuticals has a 12-month low of $8.95 and a 12-month high of $19.11. The firm has a market cap of $1.15 billion, a P/E ratio of -3.90 and a beta of 1.72.

Eyepoint Pharmaceuticals (NASDAQ:EYPT) last issued its quarterly earnings results on Wednesday, May 6th. The company reported ($0.99) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.79) by ($0.20). Eyepoint Pharmaceuticals had a negative return on equity of 110.54% and a negative net margin of 3,566.63%.The firm had revenue of $0.70 million for the quarter, compared to the consensus estimate of $0.35 million. As a group, research analysts expect that Eyepoint Pharmaceuticals will post -3.09 EPS for the current fiscal year.

About Eyepoint Pharmaceuticals

Eyepoint Pharmaceuticals, Inc is a biopharmaceutical company focused on the development and commercialization of therapies for the treatment of ocular diseases. The company’s proprietary platform centers on sustained-release formulations designed to improve drug delivery to the posterior segment of the eye, addressing conditions that often require repeated intravitreal injections or intensive topical regimens. Eyepoint’s commercial strategy combines in-house sales and marketing capabilities with targeted partnerships to bring its therapies to ophthalmologists and retina specialists across the United States.

Eyepoint’s lead products include YUTIQ, a fluocinolone acetonide intravitreal implant indicated for the prevention of relapse in non-infectious uveitis affecting the posterior segment of the eye, and DEXYCU, a dexamethasone intraocular suspension approved for postoperative inflammation following ocular surgery.